Neos angles for a $74M IPO to fund its ADHD drugs

Neos Therapeutics spelled out the terms of its pending IPO, lining up for as much as $73.6 million as it moves forward with reformulated versions of common ADHD treatments. The biotech intends to price 4 million shares at between $14 and $16 each, setting aside another 600,000 shares for its underwriters to cover overalottments. With the proceeds, Neos plans to get a trio of extended-release, orally dissolving treatments on the market. Its lead candidate, containing the same active ingredient as Ritalin, is up for an FDA decision in November, and Neos plans to submit its two amphetamine-based treatments for approval later this year. More

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.